PMN ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. (PMN) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Where they traded
Last open-market purchase: November 4, 2026 , by Williams Eugene .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Williams Eugene | Director | Buy | 26,500 | $3.43 | $90.9K | 40,213 | |
| Cashman Neil | Chief Scientific Officer | Buy | 10,000 | $3.86 | $38.6K | 14,532 | |
| Williams Eugene | Director | Buy | 1,316 | $3.99 | $5.3K | 13,713 | |
| Kaplan Johanne | Chief Development Officer | Buy | 2,280 | $13.30 | $30.3K | 6,221 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.